Génétique humaine et Embryologie

Armed Epstein Barr Virus Gene Therapy of Human Medulloblastoma Clinical Trial Phase-II (100% Powerful and Fully Treated Vaccine)

Abstract

Leen Funjan, Iman Funjan, Yara Funjan, Areen Funjan and Ahmad Funjan*

Sample of ten patients defected with medulloblastoma and rhabdomyomas are selected to treat by heavily armed vector (Epstein Barr Virus with catalase enzyme supported with long chain of phosphate group synthesized in self-funded laboratory with esterase enzyme). Ten samples of patients were invited from Jordan University of science and technology university hospital and king Hussein cancer center of these ten samples five defected with primitive neuroectodermal tumors (medulloblastoma) and the other five defected with primary tumors in infants and children of heart (rhabdomyomas). Nine of ten were selected to expose to catalase enzyme of one to six genes of the vector capsid envelop protein and it takes seven days; the last is exposed to insertion of phosphate group chain inside tumor cells by stereotactic microinjection armed (EBV) by this group inside brain tumors (medulloblastoma) and primary heart tumors (rhabdomyomas),other ten exposed directly forward to acetyl esterase gene by viral vector instead of seven and eight genes which are defected genes for human as considered other expose to three stages with effectively potential Armed vector of medulloblastoma and rhabdomyomas. This study showed significantly prolonged median survival time of 10 days for the first exposing of armed catalase enzyme in order to get catalysis procedure inside tumors itself when it reacts with c-AMP then to destroy both tumors (case of control inside tumor cells and the reagent is PCR) which can indicate the tumor controlling when the bands get the same size on gel electrophoresis 95 Kbp; the second case is using long armed chain p-group which allow to help catalase enzyme to get catalysis procedure inside brain and heart then it will react with c-AMP to destroy SHH and NOTCH genes in medulloblastoma in the brain and rhabdomyomas in the heart and it takes 25 days. The final result takes 27 days and it started from the beginning of consisting 3 factors which are 1-catalaseenzyme located from gene 1 to 6 of the vector 2-phosphate group inside tumor cells via vectors 3-estrase gene. all of these genes collected together in a single chain with 5Ë?-p-group to construct a strong-Armed vector to do as a surgical neuroonclogist in the operating room of primitive neuroectodermal tumor and primary heart tumor in infants and children to remove fully seized of tumors in both cases which has 10 patients of them by acting as precursor of c-AMP to fully destroyed SHH and NOTCH genes without altering the expression of 5-p-group; catalase enzyme; esterase enzyme in the tumor cells. We conclude that Epstein Barr Virus which Armed by catalase gene; 5 prime-p-group; esterase gene solved the biggest problem in the world medulloblastoma and rhabdomyomas in tumors in cerebellum and heart of infants and children without any toxic side effect of both diseases’ treatment. The prolonged survival time for 10 samples receiving this dose by armed vector appeared that no neurological symptoms in both tumors brain and heart.